• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab.

作者信息

Shoumariyeh Khalid, Jung Johannes, Rassner Michael, Dold Sandra Maria, Riebl Veronika, Pantic Milena, Herget Georg, Marks Reinhard, Lübbert Michael, Wäsch Ralph, Engelhardt Monika

机构信息

Department of Hematology, Oncology and Stem Cell Transplantation, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Hugstetterstr. 53, 79106, Freiburg, Germany.

Faculty of Biology, University of Freiburg, Freiburg, Germany.

出版信息

Ann Hematol. 2021 Jun;100(6):1637-1640. doi: 10.1007/s00277-021-04490-3. Epub 2021 Mar 13.

DOI:10.1007/s00277-021-04490-3
PMID:33712868
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8116235/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/30a7/8116235/6824172081e6/277_2021_4490_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/30a7/8116235/6824172081e6/277_2021_4490_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/30a7/8116235/6824172081e6/277_2021_4490_Fig1_HTML.jpg

相似文献

1
Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab.使用地西他滨/维奈克拉和达雷妥尤单抗治疗与治疗相关的急性髓系白血病及潜在的多发性骨髓瘤。
Ann Hematol. 2021 Jun;100(6):1637-1640. doi: 10.1007/s00277-021-04490-3. Epub 2021 Mar 13.
2
Molecular responses in decitabine- and decitabine/ venetoclax-treated patients with acute myeloid leukemia and myelodysplastic syndromes.地西他滨和地西他滨/维奈克拉治疗的急性髓系白血病和骨髓增生异常综合征患者的分子反应
Haematologica. 2024 Aug 1;109(8):2653-2659. doi: 10.3324/haematol.2022.281396.
3
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.在未经治疗的老年急性髓系白血病患者中，venetoclax 联合地西他滨或阿扎胞苷的安全性和初步疗效：一项非随机、开放标签、1b 期研究。
Lancet Oncol. 2018 Feb;19(2):216-228. doi: 10.1016/S1470-2045(18)30010-X. Epub 2018 Jan 12.
4
Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia.维奈克拉、FLT3抑制剂和地西他滨三联疗法治疗FLT3突变的急性髓系白血病。
Blood Cancer J. 2021 Feb 1;11(2):25. doi: 10.1038/s41408-021-00410-w.
5
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.10天阿扎胞苷联合维奈克拉用于新诊断的不适合强化化疗以及复发或难治性急性髓系白血病的治疗：一项单中心2期试验
Lancet Haematol. 2020 Oct;7(10):e724-e736. doi: 10.1016/S2352-3026(20)30210-6. Epub 2020 Sep 5.
6
Fully oral regimen with decitabine and cedazuridine plus venetoclax: a new step forward for older or unfit patients with acute myeloid leukaemia.地西他滨和西扎珠苷加维奈克拉的全口服方案：老年或身体状况不佳的急性髓系白血病患者的新进展。
Lancet Haematol. 2024 Apr;11(4):e245-e246. doi: 10.1016/S2352-3026(24)00060-7. Epub 2024 Mar 4.
7
Toward an improved understanding of hypomethylating agent and venetoclax therapies.旨在更好地理解去甲基化药物和维奈托克疗法。
Am J Hematol. 2024 Feb;99(2):152-154. doi: 10.1002/ajh.27178. Epub 2023 Dec 15.
8
Venetoclax combined with decitabine and HAAG regimen: a novel salvage strategy for relapsed/refractory T-cell acute lymphoblastic leukaemia.维奈托克联合地西他滨及HAAG方案：复发/难治性T细胞急性淋巴细胞白血病的一种新型挽救策略
Ann Hematol. 2022 Nov;101(11):2525-2528. doi: 10.1007/s00277-022-04912-w. Epub 2022 Sep 5.
9
Venetoclax and decitabine in refractory TP53-mutated early T-cell precursor acute lymphoblastic leukemia.维奈托克与地西他滨治疗难治性TP53突变的早期T细胞前体急性淋巴细胞白血病
Ann Hematol. 2022 Mar;101(3):697-699. doi: 10.1007/s00277-021-04530-y. Epub 2021 May 6.
10
Abbreviated venetoclax with decitabine or azacitidine in acute myeloid leukemia.维奈克拉联合地西他滨或阿扎胞苷简化方案治疗急性髓系白血病
Leuk Res. 2023 Nov;134:107370. doi: 10.1016/j.leukres.2023.107370. Epub 2023 Aug 16.

引用本文的文献

1
Ten Color Multiparameter Flow Cytometry in Bone Marrow and Apheresis Products for Assessment and Outcome Prediction in Multiple Myeloma Patients.用于评估和预测多发性骨髓瘤患者预后的骨髓及单采成分血十色多参数流式细胞术
Front Oncol. 2021 Aug 13;11:708231. doi: 10.3389/fonc.2021.708231. eCollection 2021.

本文引用的文献

1
Validated single-tube multiparameter flow cytometry approach for the assessment of minimal residual disease in multiple myeloma.用于评估多发性骨髓瘤微小残留病的经验证的单管多参数流式细胞术方法。
Haematologica. 2020 Oct 1;105(10):e523. doi: 10.3324/haematol.2019.238394.
2
Acute myeloid leukemia synchronous with multiple myeloma successfully treated by azacytidine/lenalidomide and daratumumab without a decrease in myeloid clone size.阿扎胞苷/来那度胺和达雷妥尤单抗成功治疗同步性急性髓系白血病合并多发性骨髓瘤，髓系克隆大小未减小。
Leuk Res Rep. 2020 Apr 23;13:100202. doi: 10.1016/j.lrr.2020.100202. eCollection 2020.
3
DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma.
DNA甲基转移酶抑制剂上调CD38蛋白表达并增强达雷妥尤单抗在多发性骨髓瘤中的疗效。
Leukemia. 2020 Mar;34(3):938-941. doi: 10.1038/s41375-019-0587-5. Epub 2019 Oct 8.
4
Multi-dimensional analysis identifies an immune signature predicting response to decitabine treatment in elderly patients with AML.多维分析确定了一个免疫特征，可预测老年 AML 患者对地西他滨治疗的反应。
Br J Haematol. 2020 Mar;188(5):674-684. doi: 10.1111/bjh.16228. Epub 2019 Oct 1.
5
Low-dose melphalan in elderly patients with relapsed or refractory acute myeloid leukemia: A well-tolerated and effective treatment after hypomethylating-agent failure.低剂量美法仑治疗复发/难治性老年急性髓系白血病：在低甲基化剂治疗失败后，一种耐受性良好且有效的治疗方法。
Leuk Res. 2019 Oct;85:106192. doi: 10.1016/j.leukres.2019.106192. Epub 2019 Aug 10.
6
Class 1 HDAC and HDAC6 inhibition inversely regulates CD38 induction in myeloma cells via interferon-α and ATRA.1类组蛋白去乙酰化酶（HDAC）和HDAC6抑制通过干扰素-α和全反式维甲酸（ATRA）反向调节骨髓瘤细胞中CD38的诱导。
Br J Haematol. 2019 Jun;185(5):969-974. doi: 10.1111/bjh.15673. Epub 2018 Nov 26.
7
CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia.CD38作为成人急性髓系白血病和T细胞急性淋巴细胞白血病的治疗靶点。
Haematologica. 2019 Mar;104(3):e100-e103. doi: 10.3324/haematol.2018.192757. Epub 2018 Sep 6.
8
Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia.达雷妥尤单抗治疗 T 细胞急性淋巴细胞白血病的临床前疗效。
Blood. 2018 Mar 1;131(9):995-999. doi: 10.1182/blood-2017-07-794214. Epub 2018 Jan 5.
9
Panobinostat induces CD38 upregulation and augments the antimyeloma efficacy of daratumumab.帕比司他可诱导CD38上调，并增强达雷妥尤单抗的抗骨髓瘤疗效。
Blood. 2017 Jun 22;129(25):3386-3388. doi: 10.1182/blood-2017-03-770776. Epub 2017 May 5.
10
A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients.简明修订的骨髓瘤合并症指数作为801例多发性骨髓瘤患者大样本队列中的有效预后评估工具。
Haematologica. 2017 May;102(5):910-921. doi: 10.3324/haematol.2016.162693. Epub 2017 Feb 2.